NERINETIDE ACETATE

Investigational

Description
Sources: https://www.ncbi.nlm.nih.gov/mesh/67542597 | https://clinicaltrials.gov/ct2/show/NCT02315443 | https://clinicaltrials.gov/ct2/show/NCT02930018

TAT-NR2B9C is a synthetic peptide fusion of the nine C-terminal residues of the NR2B subunit of the N-methyl-D-aspartate (NMDA) receptor and the cell membrane protein transduction domain of the HIV-1 tat protein. It is a postsynaptic density protein-95 (PSD95) inhibitor with neuroprotective properties. It is under development for the treatment of acute stroke and acute cerebral ischemia.

CNS Activity

Originator

Approval Year

PubMed

Title	Date	PubMed
Discovery and development of NA-1 for the treatment of acute ischemic stroke.	2018-05	29565039
Neuroprotective efficacy of poly-arginine R18 and NA-1 (TAT-NR2B9c) peptides following transient middle cerebral artery occlusion in the rat.	2017-01	27639457
PDZ protein interactions underlying NMDA receptor-mediated excitotoxicity and neuroprotection by PSD-95 inhibitors.	2007-09-12	17855605

Sample Use Guides

In Vivo Use Guide

2.6 mg/kg as a single intravenous infusion over 10 +/-1 minutes.

Route of Administration: Intravenous

Name

Type

Language

NERINETIDE ACETATE

Official Name

English

NA-1 ACETATE

Preferred Name

English

NERINETIDE ACETATE [USAN]

Common Name

English

L-VALINE, L-TYROSYLGLYCYL-L-ARGINYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-ARGINYL-L-GLUTAMINYL-L-ARGINYL-L-ARGINYL-L-ARGINYL-L-LYSYL-L-LEUCYL-L-SERYL-L-SERYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-SERYL-L-.ALPHA.-ASPARTYL-, ACETATE

Systematic Name

English

L-TYROSYLGLYCYL-L-ARGINYL-L-LYSYL-L-LYSYL-L-ARGINYL-L-ARGINYL-L-GLUTAMINYL-L-ARGINYL-L-ARGINYL-L-ARGINYL-L-LYSYL-L-LEUCYL-L-SERYL-L-SERYL-L-ISOLEUCYL-L-.ALPHA.-GLUTAMYL-L-SERYL-L-.ALPHA.-ASPARTYL-L-VALINE ACETATE SALT

Systematic Name

English

Code System Code Type Description

USAN

GH-181